Aficamten Clinical Trials (2026): 7 Studies for Obstructive Hypertrophic Cardiomyopathy (oHCM) & Obstructive Hypertrophic Cardiomyopathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Aficamten clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Obstructive Hypertrophic Cardiomyopathy (oHCM) & Obstructive Hypertrophic Cardiomyopathy) and 1,996 total planned enrollment. 4 Phase 3 Aficamten trials are listed. 2 Aficamten clinical trials are actively recruiting at 23 U.S. sites across 18 states. Most recent activity: NCT06412666 (Jan 2030).
Where to Participate: All Aficamten Trial Sites in the U.S. (23 sites across 18 states)
Every actively recruiting Aficamtentrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT06412666 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT06412666 | Map |
| CA | University of California, Los Angeles (UCLA) | Los Angeles90095 | NCT06412666 | Map |
| CO | Children's Hospital Colorado | Aurora80045 | NCT06412666 | Map |
| DC | Children's National Hospital | Washington D.C.20010 | NCT06412666 | Map |
| FL | Nicklaus Children's Hospital | Miami33155 | NCT06412666 | Map |
| IL | Ann & Robert H. Lurie Children's Hospital | Chicago60611 | NCT06412666 | Map |
| LA | Children's Hospital New Orleans | New Orleans70018 | NCT06412666 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06412666 | Map |
| MI | Children's Hospital of Michigan | Detroit48201 | NCT06412666 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06412666 | Map |
| MO | Children's Mercy Hospital | Kansas City64108 | NCT06412666 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06412666 | Map |
| NJ | Morristown Medical Center | Morristown07960 | NCT06412666 | Map |
| NY | NYP/Columbia University Medical Center | New York10027 | NCT06412666 | Map |
| NY | Children's Hospital at Montefiore | The Bronx10467 | NCT06412666 | Map |
| NC | Duke Clinical Research Institute | Durham27701 | NCT06412666 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT06412666 | Map |
| PA | Children's Hospital of Philadelphia | Philadelphia19104 | NCT06412666 | Map |
| TN | LeBonheur Children's Hospital | Memphis38103 | NCT06412666 | Map |
| TN | Vanderbilt University Medical Center | Nashville37235 | NCT06412666 | Map |
| TX | Dell Children's Hospital | Austin78723 | NCT06412666 | Map |
| TX | UT Southwestern | Dallas75390 | NCT06412666 | Map |
Aficamten clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | |||
| P2/P3 | 1 | 1 | 2 | ||
| P3 | 1 | 3 | 4 |
Recruiting Aficamten clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06412666 | CEDAR-HCMA Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | P2/P3 | Pediatric | 55 | May 2024 |
| NCT04848506 | FOREST-HCMOpen-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | P2/P3 | Symptomatic Hypertrophic Cardiomyopathy (HCM) | 900 | May 2021 |
Aficamten clinical trials by indication
Obstructive Hypertrophic Cardiomyopathy (oHCM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05767346 | MAPLE-HCM | P3 | completed | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM |
| NCT05186818 | SEQUOIA-HCM | P3 | completed | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM |
Pediatric (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06412666 | CEDAR-HCM | P2/P3 | recruiting | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). |
Obstructive Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06116968 | — | P3 | completed | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM |
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081894 | ACACIA-HCM | P3 | active not recruiting | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05924815 | — | P1 | completed | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval |
Symptomatic Hypertrophic Cardiomyopathy (HCM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04848506 | FOREST-HCM | P2/P3 | enrolling by invitation | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM |
Aficamten pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ACACIA-HCM | NCT06081894 | P3 | active not recruiting | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 500 | — |
| MAPLE-HCM | NCT05767346 | P3 | completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | — |
| SEQUOIA-HCM | NCT05186818 | P3 | completed | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 282 | — |
All Aficamten trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06412666 | CEDAR-HCM | A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | P2/P3 | recruiting | 55 | Cytokinetics | May 2024 |
| NCT04848506 | FOREST-HCM | Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM | P2/P3 | enrolling by invitation | 900 | Cytokinetics | May 2021 |
| NCT06081894 | ACACIA-HCM | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM | P3 | active not recruiting | 500 | Cytokinetics | Aug 2023 |
| NCT06116968 | An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM | P3 | completed | 40 | Corxel Pharmaceuticals | Nov 2023 | |
| NCT05767346 | MAPLE-HCM | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | P3 | completed | 175 | Cytokinetics | Jun 2023 |
| NCT05186818 | SEQUOIA-HCM | Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM | P3 | completed | 282 | Cytokinetics | Feb 2022 |
| NCT05924815 | Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval | P1 | completed | 44 | Cytokinetics | May 2023 |
Aficamten clinical trials: frequently asked questions
- How many Aficamten clinical trials are there?
- 7 Aficamten clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants. 4 are marked completed.
- Are Aficamten clinical trials recruiting in 2026?
- Yes — 2 Aficamten trials are actively recruiting in 2026, with 23 U.S. sites across 18 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Aficamten being studied for?
- Aficamten is being studied for Obstructive Hypertrophic Cardiomyopathy (oHCM), Obstructive Hypertrophic Cardiomyopathy, Healthy Participants, Symptomatic Hypertrophic Cardiomyopathy (HCM), Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy and 2 more. The trials are grouped by indication on this page.
- What phase is Aficamten in?
- Aficamten clinical trials span 4 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Aficamten clinical trials?
- The lead sponsor across the most Aficamten trials is Cytokinetics, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Aficamtenas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: